A Travere Therapeutics drug for a rare disease that can progress to kidney failure has converted its status to full FDA approval ... one of them a Novartis drug recently awarded accelerated ...
Roughly 1 percent of Americans suffer from schizophrenia, which is one of the 15 leading causes of disability worldwide, the FDA reports ... or kidney disease. Even so, the drug offers a promising ...
The US FDA has approved a new orphan drug to treat patients with Cushing’s disease who cannot be helped through surgery. Novartis’ Signifor (pasireotide diaspartate) injection has been ...
The FDA has approved Alnylam’s gene silencing drug ... As the kidney function worsens, oxalate can build up and damage other organs including the heart, bones and eyes. The disease is also ...
Travere Therapeutics TVTX announced that the FDA granted ... immunosuppressive drug Filspari (sparsentan) in IgA nephropathy (IgAN) indication, a rare progressive kidney disease.
The FDA has approved a new injectable form of the multiple sclerosis drug ocrelizumab for use in adults with relapsing and progressive forms of the disease. Multiple sclerosis occurs when the body ...
The U.S. Food and Drug Administration ... treatment of the disease. However, there have been very few new medications since then, with most subsequent FDA approvals being for variations of ...
Sept 27 (Reuters) - The U.S. Food and Drug Administration approved GE HealthCare's (GEHC.O), opens new tab diagnostic drug for use in detection of coronary artery disease, the company said on Friday.
Basel, September 17, 2024 – Novartis today announced that the US Food and Drug ... disease-free survival (iDFS) benefit was consistently observed across all patient subgroups 3-6. “The FDA ...
26, when the U.S. Food and Drug Administration (FDA) approved Cobenfy for the psychiatric ... system as a possible treatment for Alzheimer’s disease, since manipulating it seemed to reduce ...
the FDA announced Thursday. The drug, generically called Cobenfy, is the first oral medication to treat the disease that targets what are known as the brain's cholinergic receptors instead of ...
